Anti-GM1 IgG antibodies in Guillain-Barré syndrome: Fine specificity is associated with disease severity

Autores
Lardone, Ricardo Dante; Yuki, Nobuhiro; Odaka, Masaaki; Daniotti, Jose Luis; Irazoqui, Fernando Jose; Nores, Gustavo Alejandro
Año de publicación
2010
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: Clinical severity of Guillain-Barré syndrome (GBS) is highly variable, but the immunopathological reason is unknown. Objective: The study was designed to show which antibody parameters are associated with disease severity in GBS patients with serum anti-GM1 IgG antibodies. Methods: Thirty-four GBS patients with anti-GM1 IgG antibodies were grouped into two categories according to disease severity at nadir: mild (grades 1-3 by Hughes functional scale, n=13) and severe (grades 4 and 5, n=21). Titre, affinity, fine specificity and cell binding of anti-GM1 antibodies were obtained and compared between the two groups. Results: No differences in antibody titre (GM1-ELISA) or affinity were found between the two patient groups. In contrast, the severe group showed a significantly higher frequency (95%, vs 46% in the mild group, p=0.002) of specific (not cross-reacting with GD1b) anti-GM1 antibodies. In addition, the severe group also exhibited a higher antibody binding titre to cellular GM1. Conclusions: Differences in fine specificity of antibodies are strong indications that different regions of the GM 1-oligosaccharide are involved in antibody binding. High titres of specific anti-GM1 antibody binding to cellular GM1 can be explained by antigen exposure, that is, GM1 exposes or forms mainly epitopes recognised by specific antibodies, and 'hides' those involved in binding of crossreacting antibodies. Thus, the fine specificity of anti-GM 1 antibodies may influence disease severity by affecting antibody binding to cellular targets. Additionally, since antibody specificity studies are relatively easy to implement, fine specificity could be considered a useful predictor of disease severity.
Fil: Lardone, Ricardo Dante. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Centro de Investigaciones en Química Biológica de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Centro de Investigaciones en Química Biológica de Córdoba; Argentina
Fil: Yuki, Nobuhiro. Niigata National Hospital; Japón
Fil: Odaka, Masaaki. Dokkyo Medical University; Japón
Fil: Daniotti, Jose Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Centro de Investigaciones en Química Biológica de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Centro de Investigaciones en Química Biológica de Córdoba; Argentina
Fil: Irazoqui, Fernando Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Centro de Investigaciones en Química Biológica de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Centro de Investigaciones en Química Biológica de Córdoba; Argentina
Fil: Nores, Gustavo Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Centro de Investigaciones en Química Biológica de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Centro de Investigaciones en Química Biológica de Córdoba; Argentina
Materia
Gangliosides
Guillaine Barré
Antibodies
Autoimmune
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/186923
Acceder
id CONICETDig_afa41b18b0f428ed611bb5e7d61cbbc7
oai_identifier_str oai:ri.conicet.gov.ar:11336/186923
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Anti-GM1 IgG antibodies in Guillain-Barré syndrome: Fine specificity is associated with disease severityLardone, Ricardo DanteYuki, NobuhiroOdaka, MasaakiDaniotti, Jose LuisIrazoqui, Fernando JoseNores, Gustavo AlejandroGangliosidesGuillaine BarréAntibodiesAutoimmunehttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Background: Clinical severity of Guillain-Barré syndrome (GBS) is highly variable, but the immunopathological reason is unknown. Objective: The study was designed to show which antibody parameters are associated with disease severity in GBS patients with serum anti-GM1 IgG antibodies. Methods: Thirty-four GBS patients with anti-GM1 IgG antibodies were grouped into two categories according to disease severity at nadir: mild (grades 1-3 by Hughes functional scale, n=13) and severe (grades 4 and 5, n=21). Titre, affinity, fine specificity and cell binding of anti-GM1 antibodies were obtained and compared between the two groups. Results: No differences in antibody titre (GM1-ELISA) or affinity were found between the two patient groups. In contrast, the severe group showed a significantly higher frequency (95%, vs 46% in the mild group, p=0.002) of specific (not cross-reacting with GD1b) anti-GM1 antibodies. In addition, the severe group also exhibited a higher antibody binding titre to cellular GM1. Conclusions: Differences in fine specificity of antibodies are strong indications that different regions of the GM 1-oligosaccharide are involved in antibody binding. High titres of specific anti-GM1 antibody binding to cellular GM1 can be explained by antigen exposure, that is, GM1 exposes or forms mainly epitopes recognised by specific antibodies, and 'hides' those involved in binding of crossreacting antibodies. Thus, the fine specificity of anti-GM 1 antibodies may influence disease severity by affecting antibody binding to cellular targets. Additionally, since antibody specificity studies are relatively easy to implement, fine specificity could be considered a useful predictor of disease severity.Fil: Lardone, Ricardo Dante. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Centro de Investigaciones en Química Biológica de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Centro de Investigaciones en Química Biológica de Córdoba; ArgentinaFil: Yuki, Nobuhiro. Niigata National Hospital; JapónFil: Odaka, Masaaki. Dokkyo Medical University; JapónFil: Daniotti, Jose Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Centro de Investigaciones en Química Biológica de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Centro de Investigaciones en Química Biológica de Córdoba; ArgentinaFil: Irazoqui, Fernando Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Centro de Investigaciones en Química Biológica de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Centro de Investigaciones en Química Biológica de Córdoba; ArgentinaFil: Nores, Gustavo Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Centro de Investigaciones en Química Biológica de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Centro de Investigaciones en Química Biológica de Córdoba; ArgentinaB M J Publishing Group2010-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/186923Lardone, Ricardo Dante; Yuki, Nobuhiro; Odaka, Masaaki; Daniotti, Jose Luis; Irazoqui, Fernando Jose; et al.; Anti-GM1 IgG antibodies in Guillain-Barré syndrome: Fine specificity is associated with disease severity; B M J Publishing Group; Journal Of Neurology, Neurosurgery And Psychiatry; 81; 6; 6-2010; 629-6330022-30501468-330XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://jnnp.bmj.com/content/81/6/629info:eu-repo/semantics/altIdentifier/doi/10.1136/jnnp.2009.183665info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:53:32Zoai:ri.conicet.gov.ar:11336/186923instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:53:33.161CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Anti-GM1 IgG antibodies in Guillain-Barré syndrome: Fine specificity is associated with disease severity
title Anti-GM1 IgG antibodies in Guillain-Barré syndrome: Fine specificity is associated with disease severity
spellingShingle Anti-GM1 IgG antibodies in Guillain-Barré syndrome: Fine specificity is associated with disease severity
Lardone, Ricardo Dante
Gangliosides
Guillaine Barré
Antibodies
Autoimmune
title_short Anti-GM1 IgG antibodies in Guillain-Barré syndrome: Fine specificity is associated with disease severity
title_full Anti-GM1 IgG antibodies in Guillain-Barré syndrome: Fine specificity is associated with disease severity
title_fullStr Anti-GM1 IgG antibodies in Guillain-Barré syndrome: Fine specificity is associated with disease severity
title_full_unstemmed Anti-GM1 IgG antibodies in Guillain-Barré syndrome: Fine specificity is associated with disease severity
title_sort Anti-GM1 IgG antibodies in Guillain-Barré syndrome: Fine specificity is associated with disease severity
dc.creator.none.fl_str_mv Lardone, Ricardo Dante
Yuki, Nobuhiro
Odaka, Masaaki
Daniotti, Jose Luis
Irazoqui, Fernando Jose
Nores, Gustavo Alejandro
author Lardone, Ricardo Dante
author_facet Lardone, Ricardo Dante
Yuki, Nobuhiro
Odaka, Masaaki
Daniotti, Jose Luis
Irazoqui, Fernando Jose
Nores, Gustavo Alejandro
author_role author
author2 Yuki, Nobuhiro
Odaka, Masaaki
Daniotti, Jose Luis
Irazoqui, Fernando Jose
Nores, Gustavo Alejandro
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Gangliosides
Guillaine Barré
Antibodies
Autoimmune
topic Gangliosides
Guillaine Barré
Antibodies
Autoimmune
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv Background: Clinical severity of Guillain-Barré syndrome (GBS) is highly variable, but the immunopathological reason is unknown. Objective: The study was designed to show which antibody parameters are associated with disease severity in GBS patients with serum anti-GM1 IgG antibodies. Methods: Thirty-four GBS patients with anti-GM1 IgG antibodies were grouped into two categories according to disease severity at nadir: mild (grades 1-3 by Hughes functional scale, n=13) and severe (grades 4 and 5, n=21). Titre, affinity, fine specificity and cell binding of anti-GM1 antibodies were obtained and compared between the two groups. Results: No differences in antibody titre (GM1-ELISA) or affinity were found between the two patient groups. In contrast, the severe group showed a significantly higher frequency (95%, vs 46% in the mild group, p=0.002) of specific (not cross-reacting with GD1b) anti-GM1 antibodies. In addition, the severe group also exhibited a higher antibody binding titre to cellular GM1. Conclusions: Differences in fine specificity of antibodies are strong indications that different regions of the GM 1-oligosaccharide are involved in antibody binding. High titres of specific anti-GM1 antibody binding to cellular GM1 can be explained by antigen exposure, that is, GM1 exposes or forms mainly epitopes recognised by specific antibodies, and 'hides' those involved in binding of crossreacting antibodies. Thus, the fine specificity of anti-GM 1 antibodies may influence disease severity by affecting antibody binding to cellular targets. Additionally, since antibody specificity studies are relatively easy to implement, fine specificity could be considered a useful predictor of disease severity.
Fil: Lardone, Ricardo Dante. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Centro de Investigaciones en Química Biológica de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Centro de Investigaciones en Química Biológica de Córdoba; Argentina
Fil: Yuki, Nobuhiro. Niigata National Hospital; Japón
Fil: Odaka, Masaaki. Dokkyo Medical University; Japón
Fil: Daniotti, Jose Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Centro de Investigaciones en Química Biológica de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Centro de Investigaciones en Química Biológica de Córdoba; Argentina
Fil: Irazoqui, Fernando Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Centro de Investigaciones en Química Biológica de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Centro de Investigaciones en Química Biológica de Córdoba; Argentina
Fil: Nores, Gustavo Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Centro de Investigaciones en Química Biológica de Córdoba. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Centro de Investigaciones en Química Biológica de Córdoba; Argentina
description Background: Clinical severity of Guillain-Barré syndrome (GBS) is highly variable, but the immunopathological reason is unknown. Objective: The study was designed to show which antibody parameters are associated with disease severity in GBS patients with serum anti-GM1 IgG antibodies. Methods: Thirty-four GBS patients with anti-GM1 IgG antibodies were grouped into two categories according to disease severity at nadir: mild (grades 1-3 by Hughes functional scale, n=13) and severe (grades 4 and 5, n=21). Titre, affinity, fine specificity and cell binding of anti-GM1 antibodies were obtained and compared between the two groups. Results: No differences in antibody titre (GM1-ELISA) or affinity were found between the two patient groups. In contrast, the severe group showed a significantly higher frequency (95%, vs 46% in the mild group, p=0.002) of specific (not cross-reacting with GD1b) anti-GM1 antibodies. In addition, the severe group also exhibited a higher antibody binding titre to cellular GM1. Conclusions: Differences in fine specificity of antibodies are strong indications that different regions of the GM 1-oligosaccharide are involved in antibody binding. High titres of specific anti-GM1 antibody binding to cellular GM1 can be explained by antigen exposure, that is, GM1 exposes or forms mainly epitopes recognised by specific antibodies, and 'hides' those involved in binding of crossreacting antibodies. Thus, the fine specificity of anti-GM 1 antibodies may influence disease severity by affecting antibody binding to cellular targets. Additionally, since antibody specificity studies are relatively easy to implement, fine specificity could be considered a useful predictor of disease severity.
publishDate 2010
dc.date.none.fl_str_mv 2010-06
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/186923
Lardone, Ricardo Dante; Yuki, Nobuhiro; Odaka, Masaaki; Daniotti, Jose Luis; Irazoqui, Fernando Jose; et al.; Anti-GM1 IgG antibodies in Guillain-Barré syndrome: Fine specificity is associated with disease severity; B M J Publishing Group; Journal Of Neurology, Neurosurgery And Psychiatry; 81; 6; 6-2010; 629-633
0022-3050
1468-330X
CONICET Digital
CONICET
url http://hdl.handle.net/11336/186923
identifier_str_mv Lardone, Ricardo Dante; Yuki, Nobuhiro; Odaka, Masaaki; Daniotti, Jose Luis; Irazoqui, Fernando Jose; et al.; Anti-GM1 IgG antibodies in Guillain-Barré syndrome: Fine specificity is associated with disease severity; B M J Publishing Group; Journal Of Neurology, Neurosurgery And Psychiatry; 81; 6; 6-2010; 629-633
0022-3050
1468-330X
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://jnnp.bmj.com/content/81/6/629
info:eu-repo/semantics/altIdentifier/doi/10.1136/jnnp.2009.183665
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv B M J Publishing Group
publisher.none.fl_str_mv B M J Publishing Group
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269232779231232
score 13.13397

Publicaciones similares